Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23122650 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab 12 mg;   Biological: Alemtuzumab 24 mg;   Biological: Interferon beta-1a

Indicates status has not been verified in more than two years